Scientists combine CAR t therapy and bone marrow transplant to attack tough blood cancers
NCT ID NCT07162038
First seen Jun 24, 2026 · Last updated Jun 30, 2026 · Updated 3 times
Summary
This early-phase trial tests whether giving anti-CD19 CAR T cells together with a half-matched bone marrow transplant can safely treat aggressive blood cancers like leukemia and lymphoma. About 155 adults aged 18 to 75 with CD19-positive cancers will receive the combined therapy after chemotherapy. The main goal is to check safety and see if the treatment helps prevent the cancer from coming back.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Anti-CD19 CAR T cells (genetically modified immune cells) and donor bone marrow stem cells
What this could lead to
If it works, this could offer a new treatment option for people with aggressive blood cancers that have few other choices.
What could go wrong
This is a very early phase 1 trial with only 155 people, so it is not yet known if the combination is safe or effective. There are serious risks like severe immune reactions and infections.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGIC NEOPLASMS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••